EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

Zhanwei Du iD, Lin Wang iD, Yuan Bai, Yunhu Liu, Eric H Y Lau, Alison P Galvani, Robert M Krug iD, Benjamin John Cowling iD, Lauren A Meyers iD

eLife · 2024

DOI: 10.7554/elife.89801 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift eLife, 2024. Verfasst von Zhanwei Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antiviral Agents, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, ACL HHS, CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0–16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentAntiviral AgentsSARS-CoV-2COVID-19HumansRetrospective StudiesMaleHong KongFemaleMiddle AgedHospitalizationVirus SheddingAgedAdultTreatment OutcomeTime FactorsDrug Combinations

Stichwörter der Autor:innen

COVID-19PaxlovidSARS-CoV-2antiviralepidemiologyglobal healthtransmissionviruses

Substanzen

Antiviral AgentsDrug Combinations

Autor:innen und Institutionen

  • WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
  • Laboratory of Data Discovery for Health Limited, Hong Kong, China.
  • Department of Genetics, University of Cambridge, Cambridge, United Kingdom.
  • Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, United States.
  • Department of Molecular Biosciences, John Ring LaMontagne Center for Infectious Disease Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, United States.
  • Department of Integrative Biology, University of Texas at Austin, Austin, United States.

ORCID-Profile: Zhanwei Du, Lin Wang, Robert M Krug, Benjamin John Cowling, Lauren A Meyers

Förderung

  • NIAID NIH HHS
  • ACL HHS
  • CDC HHS
  • NIH HHS
  • Innovation and Technology Commission - Hong Kong
  • Health and Medical Research Fund
  • National Natural Science Foundation of China
  • National Institutes of Health

Zitieren

APA

Du, Z., Wang, L., Bai, Y., Liu, Y., Lau, E. H. Y., Galvani, A. P., Krug, R. M., Cowling, B. J., & Meyers, L. A. (2024). A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. eLife. https://doi.org/10.7554/elife.89801

Vancouver

Du Z, Wang L, Bai Y, Liu Y, Lau EHY, Galvani AP, et al. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. eLife. 2024. doi:10.7554/elife.89801

BibTeX
@article{Du2024,
  author = {Du, Zhanwei and Wang, Lin and Bai, Yuan and Liu, Yunhu and Lau, Eric H Y and Galvani, Alison P and Krug, Robert M and Cowling, Benjamin John and Meyers, Lauren A},
  title = {A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.89801}
}
Kostenlos starten →